Rapid Review Panel: product evaluation statements
Evaluations made by the Rapid Review Panel (RRP) on submitted products.
Documents
Details
These documents set out the individual product evaluations of the RRP starting May 2015. The RRP may make one of the following evaluations.
- E1: Basic research and development, validation and recent in use evaluations and trials have shown that the product is likely to have benefit(s) in improving infection prevention and control (IPC) interventions to reduce healthcare associated infections (HCAI) within the NHS; the RRP recommends considering the use of this product in the NHS to improve IPC interventions to reduce HCAIs
- E2: Basic research and development has been completed and the product may have potential value; the RRP recommends in use evaluations and trials to demonstrate improved efficiency or efficacy in improving infection prevention and control to reduce healthcare associated infections are considered within an active NHS clinical setting
- E3: Basic research and development has begun and the product may have value; the product requires head-to-head trials against existing available products to demonstrate improved efficiency or efficacy in improving infection prevention and control interventions to reduce healthcare associated infection
- E4: Potentially useful product but insufficient evidence presented; further research and development with the product as intended to be used in the NHS is required to demonstrate improvements in infection prevention and control interventions to reduce healthcare associated infections before it is ready for in use evaluation within the NHS
- E5: Evidence presented does not demonstrate that the product is more efficient or efficacious at improving infection prevention and control interventions to reduce healthcare associated infections than other available products currently in use
- E6: Evidence presented does not demonstrate that the product has a contribution to make to improvements in infection prevention and control interventions to reduce healthcare associated infections
- NE: (No Evaluation); this product is outside the remit for review or the evidence has been submitted in a way which does not allow for an evaluation by the Rapid Review Panel
Updates to this page
Published 7 May 2015Last updated 9 August 2019 + show all updates
-
Added '2203-01: Synexis Dry Hydrogen Peroxide Biodefence System' document.
-
Added '1812-01: Ultracleanse (b)' document.
-
Added: 2903-01: Prevacept Infection Control, inc PrevaCept Lock Solution.
-
Added 1803-01 Cupron Inc - Cupron Medical Textiles evaluation statement.
-
Published 1603-01: Chloraderm RRP application.
-
Added evaluations from November 2015.
-
Updated with evaluations from August 2015.
-
First published.